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ABSTRACT 
 
Aptamers, short, single stranded oligonucleotide entities, have been developed in the past 15 years against a 
plethora of targets and for a variety of applications. These range from inhibition of receptors and enzymes to the 
identification of small molecules in sensor applications, and from the development of targeted therapeutic to the 
design of novel diagnostic and imaging agents. Furthermore, aptamers have been designed for targets that cover a 
wide range of diseases, from HIV to tropical diseases, cancer and inflammation. Their easy development and 
flexibility of use and manipulation, offers further potential. In this paper we review their selection and consider 
some of the recent applications of aptamers in the design of radiopharmaceuticals for the targeted radiotherapy and 
medical imaging of disease.  
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INTRODUCTION 
 
Aptamers (from the Greek word meaning “to fit”) 
are short, 50-100 base-long, oligonucleotides 
capable of recognizing a wide range of target 
molecules, and bearing a group of characteristics 
important for the development of novel diagnostic 
and therapeutic strategies.  
Aptamers can be composed of RNA, DNA or 
modified bases, and are selected from vast 
populations of random sequences, through a 
combinatorial approach known as systematic 
evolution of ligands by exponential enrichment 
(SELEX). The selected sequences have the ability 
to recognize specific ligands by forming binding 
pockets and can bind to nucleic acids (Le Tinevez 
et al., 1998; Pileur et al., 2003), proteins (Bock et 
al., 1992; Lupold et al., 2002) or small organic 
compounds (Berens et al., 2001; Burgstaller et al., 
1996). Aptamer recognition affinity and specificity 
is comparable to those of monoclonal antibodies 
and aptamers can be selected to recognize and 
bind a wide range of targets, including toxic 
compounds and inherently non-immunogenic 
molecules that antibodies cannot be raised against. 
Furthermore, as aptamers are 10 to 100 times 
smaller than antibodies, they are expected to 
achieve higher tumour penetration than their 
counterparts (Jayasena 1999).  
These small single-stranded nucleic acids are 
claimed to act as mimics of antibodies in that they 
can recognise molecular targets with high 
specificity and are able to carry therapeutic agents, 
radioisotopes, directly to solid tumour masses or to 
individual cells that may have metastasised with 
greater efficiency (Brody and Gold, 2000; Cerchia 
et al., 2002; Sooter and Ellington, 2002).  
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When compared to antibodies, aptamers have 
advantages and disadvantages as therapeutic and 
biological reagents (Jayasena, 1999). Aptamers 
present faster tissue penetration and wider 
applicability and present the opportunity for 
simple base modifications to improve functionality 
by comparison.  Furthermore their small size 
(molecular weights between 3000 - 20000) may 
reduce steric hindrance, increasing surface 
coverage during immobilization (Deng et al., 
2001). The in vitro selection process (SELEX) can 
be more precisely monitored than can organismal 
immunization, and the affinities and specificities 
of aptamers can thus be better tailored than can 
those of antibodies. Aptamers can be more readily 
engineered than antibodies for 
biological/medicinal use (Jayasena, 1999).  
Once identified, aptamers can be reliably 
synthesized by automated methods. During 
synthesis, aptamers can be easily modified to 
facilitate further modifications such as attachment 
points for enzymes or a variety of other reagents, 
and the introduction of modified bases for 
nuclease resistance (Fig. 1) (Brody and Gold, 
2000; Eaton et al., 1997; Gewirtz, 1999). 
Furthermore, aptamers can be stored until needed 
and are resistant to denaturation and degradation 
when lyophilised.  
Due to the high degree of specificity and targeted 
nature of aptamer behaviour towards the target 
molecule, it is expected that the dosage of 
therapeutic aptamer to be used can be the smaller, 
this strategy may reduce costs and alleviate 
bystander effects caused by the aptamer-conjugate 
toxic side effects (Gewirtz, 1999). Furthermore, 
more pharmokinetic data is readily available that 
demonstrates aptamer quick clearance. PEGylation 
is currently been studied to improve aptamer 
circulation for longer periods of time (Pendergrast 
et al., 2005).  
On the other hand, aptamers are still expensive to 
produce in high quantities, mainly due to the fact 
that aptamers are a new entity and the technology 
has not evolved yet to generate large quantities of 
the entity at reasonable cost. Furthermore, the 
addition of modifications to the basic 
oligonucleotide aptamer to protect from nuclease 
degradation and improve pharmacokinetic 
properties further increases production costs. Thus, 
aptamers are still in their infancy in terms of use in 
the clinic. But their properties and development 
has attracted and still attracts increasing interest, 
demonstrated by the number of publications on 
aptamers and the current pipeline of such 
molecules in diagnostic and therapeutic 
applications. 
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Figure 1 - Possibilities for chemical modification of a nucleotide base 
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Aptamers have been selected for various purposes, 
making use of their high specificity, versatility and 
affinity in target recognition. Examples include 
aptamers that recognize proteins, peptides, dyes, 
amino acids, nucleotides, and drugs among others, 
to act as biosensors (Potyrailo et al., 1998), probes 
(Pavski and Le, 2001) and anti-clotting agents 
(Bock et al., 1992), whilst the first aptamer has 
made it to the market gaining FDA approval. 
 
Selex (Systematic Evolution of Ligands by 
Exponential Enrichment)  
SELEX is an iterative process used to identify an 
aptamer to a chosen molecular target. The method 
is based on standard molecular biological 
techniques and can be carried out following 
different experimental protocols according to the 
researcher’s choice. The process is constituted of 
three main phases: (1) selection, (2) partitioning, 
and (3) amplification (see Fig. 2).  
The process starts with the design of a large 
“library” of nucleic acid molecules generated by 
solid phase technology. Each molecule in the 
library (often as many as 1015 different 
compounds) contains a unique nucleotide 
sequence that can theoretically adopt a unique 
three-dimensional shape. Some of the most 
common structures observed, include hairpins, G-
quadruplexes, superloops etc. The SELEX library 
is generally designed with flanking primers at 
either side to allow for amplification of the 
selected pool and a variable region of anything 
from 15 up to 100 nucleotides.  
The selection phase is designed to identify those 
molecules with the greatest affinity for the target 
of interest. The library of nucleotide sequences is 
exposed to the target (a protein, small molecule, or 
supramolecular structure) by a variety of methods 
and allowed to incubate for a period of time. The 
molecules in the library with weak or no affinity 
for the target will remain free in solution, while 
those with increased capacity to bind will tend to 
associate with it.  
The partitioning phase is designed to any of 
several methods used to physically separate the 
aptamer: target complexes from the unbound 
molecules in the mixture, effectively separating 
the true binders from the weak or non-binders. The 
unbound molecules are separated and discarded. 
The target-bound molecules, among which are the 
highest affinity aptamers, are purified away from 
the target and used for the subsequent steps in the 
SELEX process. 
In the amplification phase, the captured, purified 
sequences are enzymatically amplified using PCR 
amplification, to generate a new library of 
molecules that is substantially enriched for those 
aptamers that can effectively bind to the target. 
The enriched library is used to initiate a new cycle 
of selection, partitioning and amplification.  
After a range of 5-15 cycles of the complete 
process, the library of molecules is reduced from 
trillions of unique sequences to a small number 
that bind tightly to the target of interest. Individual 
molecules in the mixture are then isolated, their 
nucleotide sequences are determined, and their 
binding affinity and specificity properties are 
characterised. In some cases, isolated aptamers are 
further refined to eliminate any nucleotides that do 
not contribute to target binding or aptamer 
structure.  
The first SELEX experiment on single stranded 
RNA oligonucleotides was published by Tuerk 
and Gold, when investigating the bacteriophage T4 
DNA polymerase (Tuerk and Gold, 1990). In 
literature we can now identify a large number of 
aptamers selected for a very broad spectrum of 
targets. Furthermore, the first aptamer has recently 
successfully reached the pharmaceutical market. 
This is an anti-VEGF aptamer for the treatment of 
macular degenerative disease that exerts its action 
by attacking the neo-vascularization characteristic 
of this disease, under the name of Macugen 
(Eyetech/Pfizer) (Ng et al., 2006; Kourlas and 
Schiller, 2006). 
 
Dna and RNA as Aptamers  
The use of single stranded oligonucleotide 
aptamers allows a large variety of DNA or RNA 
shapes and sequences to be explored. RNA or 
DNA usually create a specific cavity to enclose 
and recognize a small molecule, or adapt to the 
enclosure of a bigger molecule. Aptamers are 
thought to be mainly non-rigid molecules in the 
absence of their protein-binding partner and folded 
upon binding. The exception to the rule is found in 
G-quadruplexes such as the DNA thrombin 
aptamer that seems to hold its structure even in the 
absence of its partner. The sampling of “shape 
space” in SELEX libraries has proven effective for 
the isolation of ligands to targets that are not 
known to interact with nucleic acids 
physiologically (Macaya et al., 1995). The known 
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fact that proteins possess extensive surfaces with 
ridges, grooves, projections, and depressions, all 
covered with numerous H-bond donors and 
acceptors, suggests that proteins should be 
excellent targets for aptamer selections. The 
detection of the first nucleic acid aptamers to a 
protein that does not normally interact with RNA 
or DNA was a single stranded DNA aptamer to 
thrombin, indicating the beginning of a new class 
of thrombin inhibitors (Bock et al., 1992; Griffin 
et al., 1993). 
Numerous selections of this type have now been 
reported, and it appears that it is possible to find 
high-affinity nucleic acid aptamers for most 
proteins. This has made in vitro selection of 
aptamers an effective method for generating 
reagents that interfere with the activities of 
extracellular proteins (proteases, cell-surface 
receptors and their ligands, auto-reactive 
antibodies), implicated in diverse pathological 
conditions. Aptamers that bind to and interfere 
with the action of proteins implicated in 
pathological conditions could potentially be used 
as pharmaceutical agents. Numerous aptamers are 
now being developed as therapeutic agents. 
Aptamer have clear advantages for their use as 
therapeutics. Aptamer pharmacokinetics shortages 
of the past are now being addressed with 
appropriate chemical modifications to improve 
their stability in serum and their circulation time. 
Aptamers have now been reported to be in 
circulation in animal models up to eight hours 
when appropriately modified (Cerchia et al., 2002; 
Santulli-Marotto et al., 2003). 
Structure determination of a number of these 
aptamers has also lent insight into the folding 
capabilities and adaptive properties of nucleic 
acids in order to recognize their cognate substrates 
(Feigon et al., 1996). This recognition has been 
shown to often rely strongly on the exceptional 
propensity of the nucleic acids to assume 
secondary and tertiary structural elements as 
referred above (Dieckmann et al., 1996; Patel, 
1997). The number of possible thermodynamically 
stable structural variants available for an 
oligonucleotide sequence is much higher than the 
number of variants available for a peptide 
sequence of the same length. This is simply based 
on the ability of nucleotide bases to interact with 
each other through canonical Watson-Crick as 
well as unusual base pairing. The existence of 
oligonucleotide sequences that could assume a 
myriad of shapes within a random sequence library 
is the basis for the remarkable success of 
generating aptamers to a wide variety of target 
molecules (Lin and Patel, 1996; Patel and Suri, 
2000; Patel et al., 1997; Ye et al., 1999).  
RNA has intrinsic properties that lead to the 
formation of a variety of elaborate structures, 
some of which are able to catalyse reactions and 
others are able to function as receptors and 
ligands. Natural DNA acts almost without an 
exception as an informational macromolecule that 
exists primarily as a base-paired duplex. 
Predominantly unstructured in solution, aptamers 
fold upon association with their ligands into 
molecular architectures in which the ligand 
becomes an intrinsic part of the nucleic acid 
structure (Hermann, 2000). Single stranded DNAs 
are rarely encountered in nature, and even less 
frequently do these single stranded DNAs form 
shapes, other than the usual duplex, that serve a 
functional role. A number of compelling 
arguments can be made in support of the notion 
that certain DNAs are capable of forming 
structures that mimic those of folded RNAs, 
including ribozymes. Furthermore our 
understanding of nucleic acid recognition elements 
has also broadened as in vitro selection and 
selective evolution has been used to identify 
nucleic acid motifs with unique folding and 
ligand-binding properties (Patel, 1997).  
 
Molecular Basis of Aptamer Binding  
The molecular characteristics of aptamer 
interactions with a variety of molecular targets 
have been studied using nuclear magnetic 
resonance spectroscopy (NMR). These 
experiments offered several interesting insights 
into the interactions: (i) aptamers are folded into 
unique overall shapes to form intricate binding 
pockets to accommodate their targets; (ii) 
functional groups scattered on an aptamer are 
brought in close proximity to form a cluster of 
molecular forces that specify target interaction; 
(iii) aptamers discriminate molecules that are 
closely related to cognate targets at the atomic 
level. NMR studies of several aptamer-target 
complexes also indicated that small molecular 
targets are buried within the binding pockets of 
aptamers, leaving very little surface to interact 
with a second molecule (Berens et al., 2001; 
Dieckmann et al., 1997; Fan et al., 1996; Patel, 
1997).  
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Figure 2 - Representation of the interactive SELEX process: i) Incubate aptamer library with 
immobilised target, ii) Wash sample to remove unbound sequences, iii) Elute bound 
aptamers from target, iv) Amplify selected aptamers using PCR, v) Incubate selected 
aptamers with target, vi) After n+1 rounds, selected aptamers are cloned and 
sequenced 
 
 
 
The structure of an argininamide-DNA complex is 
one of several examples emerging recently that 
contributes to the understanding of how molecules 
adapt to recognize their substrate. Binding 
characteristics of argininamide are critical in the 
formation of the structural loop conformation of 
this DNA aptamer. The binding pocket is formed 
by unusual interactions that include the C16 
residue looping out of sequence to form a Watson-
Crick base pair across the loop with G9, and 
formation of reverse G14-T10 wobble and reverse 
A7-C15 hoogsteen pairs. These interactions are 
definitive elements in forming the deep kink in the 
DNA structure that encloses the argininamide 
ligand (Robertson et al., 2000). 
Target affinity of DNA aptamers is often based on 
the guanine quartet as the fundamental secondary 
structure unit. In general, guanine quadruplex 
structures, stabilized by guanine quartets, can be 
constructed from one, two or four oligonucleotide 
strands. When four separate strands are involved, a 
linear quadruplex results, with all deoxyguanosine 
nucleosides in the anti conformation about the 
glycosilic bond. In the other two cases, the 
quadruplexes involve folded strands and there is 
an alteration between syn and anti conformations 
for these residues (Williamson, 1994). G 
quadruplexes are remarkably stable both 
kinetically and thermodynamically because of 
tight association of cations with the guanine 
residues (Kankia and Marky, 2001).  
One of the first described examples of a protein-
specific DNA aptamer was by Bock and his 
colleagues (Bock et al., 1992), who isolated a 15-
nucleotide DNA aptamer that binds to and inhibits 
the function of human thrombin. This DNA 
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consists of stacked ‘G-quartet’ structures, similar 
to the structures that are believed to form in certain 
natural single-stranded DNAs. Two groups of 
scientists, Macaya et al.(1993) and Tsiang et 
al.(1995) have also described new thrombin-
specific DNA aptamers that also form ‘G-
quartets’. These new aptamers include additional 
paired bases that in some cases allow for a more 
tight binding to the thrombin than do aptamers 
lacking those base pairings. In addition to the 
thrombin-specific G-quartets already illustrated, 
several other guanosine-rich DNA sequences have 
been identified within in vitro selected DNAs. One 
such G-quadruplex based aptamer, actually formed 
as a dimer, is the anti-nucleolin aptamer currently 
in clinical trials by Antisoma Ltda 
(www.antisoma.com).  
RNA and DNA aptamers have been selected to 
bind the reverse transcriptase of HIV-1, and it was 
found that the aptamers bound and inhibited the 
activity of their target. Scheneider and co-workers, 
in 1995 (Schneider et al., 1995), used in vitro 
selection to isolate aptamers that inhibit the HIV-1 
reverse transcriptase (RT). After 15 rounds of 
selection from a random-sequence pool, DNA 
strands representing six different structural classes 
were isolated. The predicted structural elements of 
these molecules include internal bulges, stem-
loops and pseudoknots, a showcase for the 
structural diversity of single stranded DNA. 
Although HIV-1 RT showed a natural affinity for 
DNA, with a Kd ~ 1.4µM, several of the isolated 
aptamers showed a 1000-fold increase in affinity 
for the enzyme. It was interesting to see that 
members of both classes of aptamers could act 
both as primer/templates for HIV-1 RT and other 
DNA-polymerising enzymes. Furthermore RNA 
aptamers were also found to bend into pseudoknot 
structure and fashioned complexes with reverse 
transcriptase with a Kd of 5 nM (Famulok et al., 
2001).  
Aptamers have been shown to be neutralizers of 
R5 strains of the human deficiency virus 1 
infection by specifically binding to the CCR5-
binding site on gp120 (Dey et al., 2005; Khati et 
al., 2003), to recognize the Tenascin-C, an 
extracellular protein on the surface of glioblastoma 
cell line found in the tumour matrix (Daniels et al., 
2003), or to specifically inhibit the accumulation 
of protease-resistant forms of prion precursor 
protein (PrP) (Rhie et al., 2003; Sayer et al., 2004). 
Catalytic DNA aptamers have also been described 
by Breaker et al. (1997) and a RNA-cleaving 
aptamer by Li’s group in 2006 (Schlosser et al, 
2006). Thus, there is an increasing pool of 
biologically active aptamers about which relatively 
little is known concerning their structure and 
stability and their relationship to function.  
The objective of many aptamer selections for 
protein targets is to recover DNA molecules that 
specifically bind enzymes or receptor proteins and 
interfere with the receptor pathway. In 1996, 
Schimmel and Hale (1996) reported the selection 
of a unique type of DNA aptamer for the 
isoleucyl-tRNA synthetase of Escherichia coli. 
When this aptamer binds to the target it was found 
to promote the aminoacyl adenylate editing 
reaction that is typically induced upon binding of 
corresponding tRNA, behaving as a mimic of the 
natural binder, allowing the study of this 
interaction and an insight into the properties of 
receptor pocket and binder structure.  
RNA libraries bearing suitable modifications at the 
2’ position of the sugar have yielded aptamers that 
are nuclease resistant, thus circumventing the 
potential limitation of RNA aptamers to measure 
analytes in biological fluids that contain nucleases. 
On the other hand, compared with the unmodified 
RNA sequences, unmodified DNA sequences are 
generally more nuclease resistant. In fact, DNA 
aptamers with or without terminal modifications 
have been effective in biological fluids (Bock et 
al., 1992; Griffin and Leung, 1993). 
Therefore, it is reasonable to assume that DNA 
aptamers without further modifications could 
perform in diagnostic assays in which aptamers 
may come into contact with biological fluids for a 
brief period of time. If necessary, additional 
protection from exonucleases can be provided 
through terminal capping with small molecules 
such as an amine linker, a phosphate group, or an 
inverted thymidine residue and other unnatural 
bases (Fig. 3).  
For most diagnostic formats, terminal modification 
of aptamers is expected to be common and 
provides a route to conjugate aptamers either to 
reporter molecules or to solid supports. Modified 
nucleotides have been introduced into selection 
experiments, resulting in the isolation of aptamers 
that are surprisingly stable in vivo (Lathan and 
Toole, 1994).   
Additionally the binding affinity and specificity of 
an aptamer could be further improved by 
subjecting the sequence to a second selection 
(doped selection), in which case a biased library is 
created based on the primary sequence of an 
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existing aptamer. The biased library increases the 
complexity of molecules, mostly represented by 
the variants of the primary aptamer, which were 
lost in the early stages of selection in the 
completely randomised library by random factors 
(Knight and Yarus, 2003). 
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Figure 3 - Examples of chemical structures of unnatural base pairs that have been incorporated by 
either DNA or RNA polymerases or both. (a) isoC- isoG (Picirilli et al, 1990); (b) 
MeisoC- 6-AH-isoG (Tor, 1993); (c) 2,6-diaminopyrimidine- Xanthine (Picirilli et al., 
1990); (d) 2,4-difluorotoluene- 6-methyl purine- mimic the shape of an A-T base pair 
(Guckian et al., 1998) 
 
 
 
Aptamers as Therapeutics 
The idea of using aptamers as therapeutic 
molecules has evolved from observations of 
nature, and more specifically from the observation 
of virus and their method of control of the host 
organism. 
Several groups have made the suggestion that 
aptamers are at the forefront of the list of the most 
promising agents as potential nucleic acid 
pharmaceuticals. A whole series of aptamers that 
can bind protein targets inside and outside the cell 
can be found in the literature, which illustrates the 
potential of DNA or RNA aptamers as therapeutic 
modalities. Examples include aptamers to HIV 
related targets (Andreola et al., 2001; de Soultrait 
et al., 2002; Duzgunes 2001), hepatitis C (Biroccio 
et al., 2002; Hwang et al., 2000; Vo et al., 2003), 
Trypanosoma cruzi (Homann and Goringer, 1999; 
Homann and Goringer, 2001; Ulrich et al., 2002), 
prion proteins (Sayer et al., 2004; Weiss et al., 
1997), thrombin (Bock et al., 1992; Griffin et al., 
1993; Holland et al., 2000), anti-angiogenesis 
vascular endothelial growth factor (Blank et al., 
2001; White et al., 2003), prostate specific 
membrane antigen (Lupold et al., 2002), among 
many others. Aptamers against the nucleolin are 
currently in clinical trials for the treatment of 
cancer with very promising results 
(www.antisoma.com). One of the success stories is 
the anti-VEGF aptamer as referred before 
(www.eyetk.com). The pegylated anti-VEGF 
aptamer has been recently FDA approved, and it 
was developed to target the abnormal blood vessel 
growth and leakage that leads to blindness 
(Carrasquillo et al., 2003). The anti-VEGF 
aptamer neutralizes the abnormal VEGF presence 
in the eye thus preventing its binding to the 
receptor. The anti-VEGF aptamer has 
demonstrated efficacy in several in vitro and in 
vivo models.  
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Another success story is the E2F decoy aptamer 
that binds the transcription factor E2F, aimed at 
reducing the proliferation of cardiac and vascular 
cells in cardiovascular diseases as well as in the 
development of malignancies (Fabbrizio et al., 
1999). This aptamer is a naturally developed 
aptamer, because it contains a known consensus 
sequence that is found naturally in the human 
body. This aptamer is currently in Phase three 
trials study by Corgenetech, Inc. and being 
evaluated for its efficacy at restraining coronary 
and peripheral vascular graft failure. 
Aptamers also present the possibility to work as 
antidotes and more importantly the potential of 
creating a self-antidote, simply through the 
creation of a self-aptamer that disrupts the 
interaction with the target, thus allowing for a 
controlled therapy. This feature is not usually 
present in any of other biological therapy.  
However, drawbacks such as their cost, synthesis, 
bioavailability, pharmacokinetics properties and 
delivery hindered aptamers from immediate 
application in the pharmaceutical industry and 
more importantly the fact that antibodies are a 
proven biological therapeutic and thus aptamers 
would need to be more flexible, more stable and 
more efficient than antibodies in order to replace 
the later. Thus, aptamer development needs to 
focus on their advantages in relation to other more 
proven biological therapeutics and the possibilities 
they present.  
 
Aptamers as Radiopharmaceutical Tools 
The advent of techniques such as SELEX has 
allowed the study and manipulation of nucleic 
acids and has propelled the discovery of molecular 
tools for the treatment of human disease. Equipped 
with these new tools, the implementation of simple 
steps for the formation of a new class of 
therapeutic agents was one step away. The idea of 
attaching radionucleotides to a biological molecule 
is not new (Bernardo-Filho et al., 2005). Long and 
detailed studies have been carried out in the past 
with some success with antibodies, peptides or 
antisense targeting. Aptamer labelling was a 
natural step in the direction of molecular targeted 
radiopharmaceutical development, propelled both 
by the understanding of the biological properties 
of these molecules, specially their chemical 
malleability and pharmacokinetics, and the 
simplicity of the chemistry involved in the 
labelling of aptamers for pharmacoimaging and 
pharmacotherapy (Britz-Cunningham and 
Adelstein, 2003; Cerchia et al., 2002; Urbain, 
1999).   
Two DNA aptamers directed at two separate 
exosites on the human alpha-thrombin have been 
evaluated for they’re potential as thrombus 
imaging agents. Both aptamers were analysed and 
ODN2 was found to be suitable for imaging with 
rapid clearance rates. However, the conclusions of 
the study also found that the slow mass transfer to 
the clot worked against the in-vivo thrombin-
dependent imaging (Doughan et al., 2003). More 
recently an aptamer that binds to the extracellular 
matrix protein Tenascin-C was 99mTc-labeled and 
analysed for the potential use as 
radiopharmaceutical in a variety of animal models. 
In this study rapid uptake and rapid clearance of 
the radiolabeled aptamer from blood and other 
tissues provided clear tumour imaging, thus 
suggesting potentially imaging and therapeutic 
applications (Hicke et al., 2006). 
 
Aptamer Labeling with Radiometals 
The introduction of radiometals into aptamers has 
been carried out by chelation of the metal with a 
suitable binding ligand (bifunctional chelator), 
followed by conjugation to the aptamer via a 
reactive functional group. Such groups include a 
3’-amino modification, or a 5’-linker equipped 
with an amino terminus, which enables the 
attachment of the complex through an amide bond. 
The chemistry is largely based on the chemistry 
developed for proteins and peptides.  
Aptamer labeling with technetium, the most 
common radiometal used in imaging, has been 
reported by Hilger et al. (1998). The bifunctional 
N3S-type peptide-based chelator MAG2 was 
synthesized in the S-acetyl-protected form. 
Activation of the carboxylic acid with N-
hydroxysuccinimide ester formation enabled 
conjugation to an L-Selectin binding aptamer 
through a 5’-(6-aminohexyl)-phosphato linker. 
Cleavage of the sulfur protection, followed by 
treatment with sodium pertechnetate yielded the 
Tc-aptamer complex in excellent yield (90-95% 
yield). The same bifunctional chelator and linker 
were used by Schmidt et al. (2004) to label a series 
of locked nucleic acids. An interesting feature of 
aptamer labeling is the possibility to carry out the 
complexation step in the final stage of the 
conjugate synthesis, as aptamers do not get 
denatured even at high temperatures. This is 
particularly important in the case of short-lived 
isotopes.  
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Charlton et al. (1997) have reported the labeling of 
an aptamer inhibitor of human neutrophil elastase 
with MAG2-complexed 99mTc. The comparison 
of the labeled aptamers with labeled a labeled IgG 
showed that the aptamer displayed rapid 
accumulation in the tumor and rapid clearance. 
Tumor-to-blood ratios after 2 h was approximated 
4 in the case of the aptamer, while for the antibody 
it peaked at 3-4 at 3 h. The superior T/B ratios 
were due to the rapid clearance of the aptamer 
conjugate from the non-target (non-inflamed) 
tissue, while there was little or no clearance of the 
IgG. 
An anti-Tesascin-C aptamer (TTA1) was labeled 
with 99mTc, and the biodistribution of the 
conjugate was investigated in glioblastoma and 
breast cancer tumor xenografts (Hicke et al., 
2006). The impact of the metal chelate (MAG2-
Tc) on biodistribution was evaluated by 
conjugation to both TTA1 and PEG-ylated TTA1. 
The MAG2 moiety was conjugated to the 
oligonucleotide via a 5’-amino group. It was found 
that radiolabeling did not affect the affinity of the 
aptamer to Tenascin-C. The tumor-to-blood ratio 
was > 50 three hours post injection, and > 180 
after 16 h, while the control antibody required 40 h 
for a T/B ratio of 5. 
An anti-MUC1 aptamer was labeled with 
technetium complexed with four different 
bifunctional chelators bearing carboxylic acid 
bioconjugatable functionalities (Borbas et al., 
2007). The complexes were formed by reduction 
of the pertechnetate with sodium borohydride, 
followed by treatment with a solution of the 
chelator. The complexes were conjugated without 
isolation to a 3’-amino group in the aptamer in 
standard EDCI-mediated peptide bond formations. 
The chelators tested were commercially available 
MAG3, DOTA, meso- tetrakis (p-carboxyphenyl) 
porphyrin and a cyclen (1,4,7,10-
tetraazacyclododecane) derivatised with a 
methionine arm (MetCyc) (Fig. 4). 
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Figure 4 - The novel cyclen based ligand with a methionine arm offers additional stability for the 
metal, whilst the carboxylic group allows coupling to an amino-modified aptamer 
using standard peptide chemistry 
 
 
The presence of four carboxylates in DOTA 
enabled the attachment of four aptamer molecules 
to a central complex. The increased molecular 
weight of the tetrameric conjugate as opposed to 
the monomeric ones resulted in increased tumor 
retention and improved pharmacokinetic 
properties. With the exception of the porphyrin, all 
the tested chelators performed suitably, and 
aptamer labeling was typically >90%. Although 
the porphyrin was an unappealing chelator for 
techentium, it could be much better suited for 
other radiometals, such as copper, as porphyrin-
copper(II) complexes are particularly stable. 
 
 
Antibodies VS Aptamers  
In various published studies, antibodies and 
aptamers have been extensively compared and 
scrutinized (Brody and Gold, 2000; Jayasena, 
1999). Aptamers have been hailed as the new 
biological molecule with enough superiority to 
slowly replace antibodies. An account of these 
differences is summarised below. 
Antibodies have, for many decades, been at the 
forefront of biological therapies, but their swift 
development has been countered by a variety of 
barriers that are being slowly overcome (Cosmas 
et al., 1993). The antibody identification process 
traditionally starts within an animal; this process 
allows for the creation of many specific antibodies 
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with the physiological constraints already in place. 
However, the antibody generation against 
molecules that are not well tolerated by animals, 
such as toxins, becomes difficult. Furthermore 
antibodies against molecules that are inherently 
less immunogenic are also difficult to rise.  
The identification and production of monoclonal 
antibodies is laborious and can become very 
expensive (Berkower, 1996). Moreover, the 
production of antibodies has challenges of its own. 
Frozen stocks of antibody-producing cells should 
be stored at multiple sites to overcome accidental 
losses or death of cell lines (Berkower, 1996). 
Typically, growing the hybridomas in the 
peritoneal cavities of animals and purifying the 
antibody from ascitic fluid results high yields of 
monoclonal antibodies. However, hybridomas are 
difficult to grow in vivo, thus restricting this route 
of antibody production (Berkower, 1996). By and 
large, the generation of hybridomas are restricted 
to rat and mouse, limiting the use of antibodies in 
therapeutic applications. Some advances have 
been achived in this area with the emergence of 
combinatorial library technology, where antibodies 
are selected from a library expressed on the 
surface of M13 filamentous phage and then 
panned in an antigen dependent manner (Clackson 
et al., 1991; Huse et al., 1999). Antibodies of non-
human origin have implications in diagnostic 
applications as well. Heterophilic antibodies 
(human antibodies that recognize antibodies of 
non-human origin) that exist in humans could 
potentially link a capture antibody with a detector 
antibody of non-human origin in the absence of 
the specific analyte, leading to false-positive 
results. Rheumatoid factors and auto-antibodies 
have been shown to interfere with immunoassays 
(Kosmas et al., 1993).  
The performance of the same antibody tends to 
vary from batch to batch, requiring immunoassays 
to be re-optimised with each new batch of 
antibodies. As the production of antibodies is 
subject to in vivo variations, the identification of 
antibodies is also restricted by in vivo parameters. 
In other words, identification of antibodies that 
could recognize targets under conditions other 
than physiological is not feasible. The kinetic 
parameters of antibody-target interactions cannot 
be changed on demand. Antibodies are sensitive to 
temperature and undergo irreversible denaturation. 
They also have a limited shelf life (Berkower, 
1996).  
It is however important to outline that various 
approaches are being developed to circumvent 
limitations associated with the current hybridoma-
based antibody technology. These approaches 
include the well-established humanization of 
antibodies (Hwang and Foote, 2005), displaying 
peptide libraries on phage display technology 
(Fitzgerald, 2000), ribosomes (Glickman and 
Raveh, 2005), yeast two-hybrid system for 
selecting functional intrabodies (Hyland et al., 
2003), single chain antibodies (Tungpradabkul et 
al., 2005), and they are all at various stages of 
development. 
Alternatively, aptamers have been developed in 
the last decade alongside antibodies with the 
promise of being equal or superior molecules that 
can overcome certain disadvantages of the 
antibody technology (Jayasena, 1999), as outlined 
in the previous sections. Aptamers chief advantage 
lies on their technical versatility and applicability 
to a wide array of target molecules. It is expected 
that certain applications that use antibodies will 
gradually be used in conjunction or replaced by 
aptamers because of their inherent characteristics 
(Nimjee, 2005). The question now remains 
whether these advantages are unique enough to 
prompt researchers to overcome some of the 
daunting disadvantages and establish aptamers as 
diagnostic and therapeutic agents in the clinic. 
 
 
RESUMO 
 
Aptâmeros são pequenos oligonucleotídeos de 
cadeia simples, que têm sido desenvolvidos nos 
últimos 15 anos para diversos alvos e com várias 
aplicações. Essas incluem a inibição de receptores 
e enzimas, para a identificação de pequenas 
moléculas “sensoras” e o desenvolvimento de 
alvos terapêuticos para diagnóstico e imagem. 
Além disso, aptâmeros também foram 
desenvolvidos para alvos que incluem diferentes 
doenças, tais como HIV, doenças tropicais, câncer 
e inflamação. O fácil desenvolvimento, 
flexibilidade de uso e manipulação sugere outras 
aplicações potenciais. Esta revisão apresenta uma 
seleção de trabalhos e considera alguns dos mais 
recentes usos dos aptâmeros para o 
desenvolvimento de radiofármacos para 
radioterapia e diagnóstico por imagens. 
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